|
Welcome
|
|
12 March 2010
|
|
|
| home | my details | ISRCTN Register | mRCT | UKCTG | links | information | press |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
| [ Print-friendly version ] |
| Cannabis fOr Management of Pain: Assessment of Safety Study: COMPASS |
| ISRCTN | ISRCTN19449752 |
| ClinicalTrials.gov identifier | |
| Public title | Cannabis fOr Management of Pain: Assessment of Safety Study: COMPASS |
| Scientific title | |
| Acronym | COMPASS |
| Serial number at source | MOL-66262 |
| Study hypothesis | The rationale for this long-term follow-up safety study is to facilitate a better understanding of how patients use cannabis, the number and nature of side effects in relation to exposure, and it would allow some exploration of the effects of cannabis on certain symptoms. The information gathered will assist in policy decisions and inform discussions of cannabis use between patients and physicians. |
| Ethics approval | Approval received from the Research Ethics Committee of the McGill University Health Centre, Montreal General Hospital (Canada) on the 14th January 2004 (ref: NREC#03-024). |
| Study design | Multicentre, two arm, open-label observational cohort safety study with one-year follow up. |
| Countries of recruitment | Canada |
| Disease/condition/study domain | Chronic non-malignant pain |
| Participants - inclusion criteria |
Experimental arm and control arm (common criteria):
1. Adults 18 years or older, either sex 2. Chronic non-cancer pain for six months or longer 3. Moderate to severe pain (average weekly pain score on a 0 to 10 point scale of 5 or greater) 4. Ability to comply with protocol requirements 5. Proficient in reading and writing in English or French 6. Patient willing and able to give informed consent Specific criteria (in addition to common criteria): 1. Experimental arm: conventional treatments have been considered medically inappropriate or inadequate 2. Control arm: patients must have received any prescription from the study physician in the past three months |
| Participants - exclusion criteria |
Experimental arm and control arm (common criteria):
1. Pregnant or breast-feeding women 2. History of psychosis, including mental illness that could put subjects at risk during the study 3. Significant and unstable ischaemic heart disease or arrhythmia 4. Significant and unstable bronchopulmonary disease 5. Discordance between self-reported drug use and urine drug screening 6. History of drug dependency (including cannabis), or at risk of drug dependency identified by Drug Abuse Screening Test (DAST) and urine drug testing 7. Concurrent involvement in other clinical trial(s) Specific criteria (in addition to common criteria): 1. Control arm: current cannabis use (use in the past month) |
| Anticipated start date | 01/01/2005 |
| Anticipated end date | 31/12/2007 |
| Status of trial | Completed |
| Patient information material | |
| Target number of participants | 1400 |
| Interventions |
Experimental group: cannabis, daily up to 3g/day
Control group: standard therapy for pain Contact for public queries: Nicole Poitras Study Coordinator Tel: +1 514 934 1934 ext: 44349 Fax: +1 514 934 8491 e-mail: nicole.poitras@muhc.mcgill.ca |
| Primary outcome measure(s) |
1. Adverse events and adverse drug reactions*:
Time of measurement: this will be reported by the subjects during interviews at clinic visits, during telephone contacts, or at any time by calling the local study nurse up to one year 2. Neurocognitive tests (Wechsler scales, for experimental arm [cannabis users] and control arm [non-cannabis users]): Time of measurement: baseline, six months and one year *An "adverse event" means any adverse occurrence in the health of a clinical trial subject who is administered a drug, which may or may not be caused by the administration of the drug, and includes an adverse drug reaction. An "Adverse Drug Reaction (ADR)" means any noxious and unintended response to a drug that is caused by the administration of any dose of the drug. |
| Secondary outcome measure(s) |
1. Satisfaction with the study drug: a global rating of change in patient satisfaction with the provided drug will be generated for subjects and physicians using the Clinician’s Global Impression of Change (CGIC) scale. This is an observational scale of global evaluation, which assesses the changes in degree of illness in relation to the original assessment, not just due to the study drug. The scale has only one item that measures global change of the illness (improvement or worsening) by the clinician and by the patients, separately, on a seven-point scale from zero to six. Change in satisfaction on this scale will also be examined with other measures of satisfaction such as dropout rates
Time of measurement: Experimental arm (cannabis users): one month, two months, three months, six months, nine months, one year Control arm (non-cannabis users): six months, one year 2. Effects on symptoms and quality of life: a. Pain intensity: effects on pain intensity will be recorded using 0 to 10 numerical rating scales (0: no pain, 10: worst) b. McGill Pain Questionnaire (MPQ): pain quality will be recorded using the MPQ. The MPQ is a self-administered questionnaire that evaluates the sensory, affective, and evaluative dimensions of pain and provides global scores and subscale scores for each of these dimensions c. Edmonton Symptom Assessment Scale (ESAS): other symptoms will be monitored using the validated ESAS. The ESAS evaluates eight symptoms on visual analogue scores d. Profile of Mood States (POMS): the POMS was developed to assess transient distinct mood states and has become the most popular and widely used tool to assess mood e. Quality of life will be followed using the 36-item Short Form health survey (SF-36): SF-36 is a generic measure of perceived health status that incorporates behavioural functioning, subjective well-being and perceptions of health by assessing eight health concepts Time of measurement: Experimental arm (cannabis users): baseline, one month, two months, three months, six months, nine months, one year Control arm (non-cannabis users): baseline, six months, one year 3. Feasibility of web-based adverse event reporting: will be assessed by ongoing documentation of the study monitoring process, specifically recording the issues that may arise during data collection using web-based forms (errors, misunderstandings, etc.,) and the manner and success of their resolution |
| Sources of funding | Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca/ (ref: MOL-66262) |
| Trial website | |
| Publications | |
| Contact name | Dr Mark Adrian Ware |
| Address |
McGill University Health Centre
Pain Centre Montreal General Hospital, Room E19.145 1650 Cedar Avenue Montreal |
| City/town | Quebec |
| Zip/Postcode | H3G 1A4 |
| Country | Canada |
| Sponsor | McGill University Health Centre (Canada) |
| Address |
Research Institute
1650 Cedar Ave Montreal |
| City/town | Quebec |
| Zip/Postcode | H3G 1A4 |
| Country | Canada |
| Tel | +1 514 934 1934 ext: 44580 |
| Fax | +1 514 934 8261 |
| lynn.derycapes@muhc.mcgill.ca | |
| Sponsor website: | http://www.muhc.ca/ |
| Date applied | 11/05/2007 |
| Last edited | 18/04/2008 |
| Date ISRCTN assigned | 11/05/2007 |
|
|
|
|
|
| © ISRCTN | |
|
|
|
|